Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Piper Sandler adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) shares, reducing it from the previous $1,195.00 to $1,013.00. Despite this change, the firm maintained its ...

Lung cancer survival without treatment is shorter than survival with treatment. People with untreated non-small cell lung cancer—the most common type—typically live between five and 12 months after ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

The study enrolled women with squamous cell carcinoma and adenocarcinoma forms of cervical cancer, and the death rate in those subgroups was reduced by 27% and 44%, respectively, with Libtayo.

However, Regeneron recently announced that its PD-1 inhibitor LIBTAYO had met its primary endpoint among patients with high risk cutaneous squamous cell carcinoma (CSCC). This positive news in ...